Requip is a brand-name medication that contains ropinirole as its active ingredient. Ropinirole belongs to the dopamine-agonist class of drugs and is used primarily in the field of neurology. In Hong Kong, Requip is available only by prescription and is supplied as a pill in the strengths 0.25 mg, 0.5 mg, 1 mg, and 2 mg. The product is regulated by the Hong Kong Department of Health (HKDH) and must be prescribed by a qualified healthcare professional.
Ropinirole mimics the action of dopamine, a neurotransmitter that plays a critical role in movement control. By binding to dopamine-type 2 (D₂) receptors in the brain, ropinirole stimulates the same pathways that are deficient in Parkinson’s disease and certain movement disorders. This activation helps to:
Ropinirole is absorbed rapidly after oral administration, reaching peak plasma concentrations within 1-2 hours. It is metabolised mainly by the liver enzyme CYP1A2 and has an elimination half-life of approximately 6 hours, which supports multiple daily dosing for consistent symptom control.
Requip is officially approved in Hong Kong for the following indications:
These approvals are based on extensive clinical trials that demonstrated symptomatic improvement and an acceptable safety profile for the listed dosages.
While Requip is not formally approved for other conditions, some peer-reviewed studies have examined its utility in additional neurological settings. Off-label applications include:
Disclaimer: Off-label use requires medical supervision and an individualized risk assessment. These applications have not been approved by the HKDH.
If you are unsure about any potential interaction, discuss all current medications, supplements, and herbal products with your pharmacist or physician.
Standard dosing for Parkinson’s disease
Start with 0.25 mg once daily (usually at bedtime).
Increase by 0.25 mg every 3-7 days based on tolerance and clinical response.
Typical maintenance ranges from 0.5 mg to 2 mg three times daily, not exceeding the available strengths.
Standard dosing for restless-legs syndrome
Begin with 0.25 mg once daily in the evening.
Titrate up to 0.5 mg, 1 mg, or 2 mg once daily as needed, usually after 3 days at each dose level.
Special populations
Elderly - consider initiating at the lowest dose (0.25 mg) and titrating more slowly.
Hepatic impairment - avoid doses above 2 mg per day; monitor liver function tests.
Administration guidance
Swallow the pill whole with a glass of water.
Do not crush, split, or chew unless instructed by a healthcare provider.
Store at room temperature, away from moisture and direct sunlight.
Missed dose
If you forget a dose, take it as soon as you remember unless it is almost time for the next scheduled dose. Do not double up.
Overdose
Symptoms may include severe nausea, vomiting, dizziness, or fainting. Seek emergency medical care; supportive measures and gastrointestinal decontamination are the primary treatments.
Discontinuation
Sudden withdrawal can precipitate rebound motor symptoms. Taper the dose gradually under medical supervision.
Dosing must always be individualized by your prescribing clinician, who will consider your specific health profile and response to therapy.
If new or worsening symptoms arise, contact your healthcare provider promptly.
This article provides educational information about Requip and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Requip is usually taken once daily at bedtime for restless-legs syndrome to reduce night-time symptoms, or multiple times per day for Parkinson’s disease. Timing should follow your doctor’s instructions to balance efficacy and side-effect risk.
Impulse-control urges are a known risk. Report the change to your prescriber immediately; they may adjust the dose or switch to an alternative therapy.
Yes, but keep the medication in its original packaging with a copy of the prescription. Some countries may require documentation for controlled neurological drugs, so carrying a letter from your doctor is advisable.
Caffeine does not have a direct interaction with ropinirole, but it can exacerbate insomnia or jitteriness. Limit excessive caffeine if you notice increased restlessness.
Signs include rash, itching, swelling of the face or throat, and difficulty breathing. Seek emergency medical care if any of these symptoms appear.
Ropinirole does not typically interfere with routine laboratory tests, but liver function tests may be monitored periodically, especially in patients with hepatic concerns.
Combining ropinirole with other sedatives can increase drowsiness. Consult your pharmacist before adding any sleep-aid products.
Ropinirole is not approved for pediatric use in Hong Kong. Its safety and efficacy have not been established in children.
Both contain the same active ingredient, ropinirole, and have comparable efficacy. The brand may have specific inactive ingredients or packaging, but the therapeutic effect is equivalent.
Patients often experience a reduction in symptoms within 1-2 weeks, though optimal benefit may require gradual dose titration over several weeks.
